Nektar Therapeutics (BMV:NKTR)
| Market Cap | 19.69B -12.6% |
| Revenue (ttm) | 940.61M -16.6% |
| Net Income | -3.19B |
| EPS | -120.84 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1,584.15 |
| Previous Close | 1,584.15 |
| Day's Range | 1,584.15 - 1,584.15 |
| 52-Week Range | 165.00 - 1,742.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col... [Read more]
Financial Performance
In 2025, Nektar Therapeutics's revenue was $55.23 million, a decrease of -43.89% compared to the previous year's $98.43 million. Losses were -$164.08 million, 37.9% more than in 2024.
Financial numbers in USD Financial StatementsNews
Nektar Therapeutics Transcript: Jefferies Global Healthcare Conference
REZPEG's phase II profile showed deep, durable responses in AD and AA, supporting pivotal programs. AD phase III began in summer 2026; AA phase III is slated for December 2026, with first AD readouts expected mid-2028.
Nektar Therapeutics Transcript: UBS Global Biopharma Conference 2026
REZPEGâs Phase II results highlighted durable effects in atopic dermatitis and alopecia areata, including persistence after treatment ends. Three atopic dermatitis Phase III studies are underway, with the first readout expected around summer 2028; alopecia and vitiligo studies are also advancing.
Nektar price target lowered to $149 from $153 at Canaccord
Canaccord analyst Edward Nash lowered the firmâs price target on Nektar (NKTR) to $149 from $153 and keeps a Buy rating on the shares. The firm updated its model followingâŠ
Nektar price target lowered to $40 from $50 at Wedbush
Wedbush lowered the firmâs price target on Nektar (NKTR) to $40 from $50 and keeps a Neutral rating on the shares. The firm remains cautious on Nektarâs commercial prospects inâŠ
Nektar Therapeutics Earnings Call Transcript: Q3 2026
REZPEGâs phase III atopic dermatitis program is underway, with alopecia areata startup planned for December 2026 and initial AD data expected in summer 2028. Q3 net loss was $56 million; year-end cash and investments are forecast above $840 million.
Nektar Therapeutics Earnings release: Q3 2026
Nektar Therapeutics released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Nektar Therapeutics Quarterly report: Q3 2026
Nektar Therapeutics has published its Q3 2026 quarterly earnings report on November 12, 2026.
Nektar reports Q3 adjusted EPS ($1.63), consensus ($2.11)
Reports Q3 revenue $9.4M, consensus $10.4M. âThis was a pivotal quarter for Nektar (NKTR) as we moved rezpegaldesleukin quickly into Phase 3 development,â said Howard Robin, President and Chief Execut...
Nektar Therapeutics Announces Third Quarter 2026 Financial Results
SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:Â NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Ca...
Nektar Therapeutics to Participate in Two Investor Conferences in November
SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:Â NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS Global Biopharma...
Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after...
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors gr...
Nektar initiated with an Outperform at Leerink
Leerink analyst Will Soghikian initiated coverage of Nektar (NKTR) with an Outperform rating and $130 price target Rezpegaldesleukin, a potentially first-in-class biologic that stimulates regulatory T...
Nektar initiated with a Neutral at UBS
UBS initiated coverage of Nektar (NKTR) with a Neutral rating and $53 price target Nektar is the leader in the regulatory T cell space, with a promising immunology approach andâŠ
3 âStrong Buyâ High-Risk/High-Reward Stocks to Bank on for 100%+ Upside Potential
Nektar Therapeutics ($NKTR), Applied Aerospace & Defense ($AADX), and T1 Energy ($TE) are three high-risk, high-reward stocks backed by Wall Street. They are all currently rated a Strong Buy andâŠ
Nektar initiated with a Market Perform at Raymond James
Raymond James initiated coverage of Nektar (NKTR) with a Market Perform rating and no price target Treg modulation is âa scientifically compelling approach in autoimmune diseaseâ and rezpegaldesleukin...
Nektar 60% selloff brings âattractive buying opportunity,â says Citi
Citi views the 60% selloff in shares of Nektar (NKTR) since the April highs as an âattractive buying opportunity.â There has been no negative news that impacts rezpegaldesleukinâs clinical orâŠ
Nektar selloff yesterday overdone, says H.C. Wainwright
H.C. Wainwright analyst Arthur He views the 22% pullback yesterday in shares of Nektar (NKTR) as overdone. The company presented 52-week treatment and six-month off-treatment data from the Phase 2bâŠ
Nektar selloff after rezpegaldesleukin data âunwarranted,â says Jefferies
Jefferies analyst Roger Song sees the selloff in shares of Nektar (NKTR) following updated rezpegaldesleukin data âunwarranted.â The off-treatment data âdoes not change our thesis,â says the analyst, ...
William Blair says rezpeg data a positive for Nektar
William Blair analyst Andy Hsieh maintained an Outperform rating on Nektar (NKTR) Therapeutics following updated rezpegaldesleukin, or rezpeg, datathat the firm believes âadds to the growing body of e...
Nektar Stock Sinks Despite Promising Hair Loss Treatment Data
Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug.
Nektar Therapeutics Transcript: Study update
REZPEG demonstrated robust, durable efficacy and a favorable safety profile in severe alopecia areata, with 63% of responders maintaining hair regrowth six months after stopping treatment. Biomarker data in atopic dermatitis confirmed rapid, broad immune modulation, supporting REZPEGâs differentiated mechanism and potential as a first-line therapy.
Nektar Therapeutics Slides: Study update
Nektar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
